Jpmorgan Chase & CO Nuvalent, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Nuvalent, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 34,709 shares of NUVL stock, worth $2.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,709

Previous 32,045 8.31%

Holding current value

$2.7 Million

Previous $2.43 Million 46.09%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Dec 26, 2024	BUY	$67.44 - $112.17 $179,660 - $298,820	2,664 Added 8.31%	34,709 $3.55 Million
Q3 2024 Nov 08, 2024	BUY	$67.44 - $112.17 $179,660 - $298,820	2,664 Added 8.31%	34,709 $3.55 Million
Q2 2024 Dec 26, 2024	SELL	$62.76 - $81.61 $167,192 - $217,409	-2,664 Reduced 7.68%	32,045 $2.43 Million
Q2 2024 Aug 12, 2024	SELL	$62.76 - $81.61 $178,238 - $231,772	-2,840 Reduced 8.14%	32,045 $2.43 Million
Q1 2024 Dec 26, 2024	BUY	$72.35 - $88.99 $12,733 - $15,662	176 Added 0.51%	34,885 $2.62 Million
Q1 2024 May 10, 2024	SELL	$72.35 - $88.99 $1.05 Million - $1.29 Million	-14,460 Reduced 29.3%	34,885 $2.62 Million
Q4 2023 Dec 26, 2024	BUY	$42.42 - $80.28 $620,859 - $1.17 Million	14,636 Added 42.17%	49,345 $3.63 Million
Q4 2023 Feb 12, 2024	BUY	$42.42 - $80.28 $359,806 - $680,934	8,482 Added 20.76%	49,345 $3.63 Million
Q3 2023 Nov 14, 2023	BUY	$39.12 - $49.85 $155,775 - $198,502	3,982 Added 10.8%	40,863 $1.88 Million
Q2 2023 Aug 11, 2023	SELL	$23.58 - $44.68 $8.97 Million - $17 Million	-380,323 Reduced 91.16%	36,881 $1.56 Million
Q1 2023 May 18, 2023	BUY	$25.42 - $33.52 $391,976 - $516,878	15,420 Added 3.84%	417,204 $10.9 Million
Q1 2023 May 11, 2023	SELL	$25.42 - $33.52 $626,399 - $825,999	-24,642 Reduced 5.78%	401,784 $10.5 Million
Q4 2022 Feb 13, 2023	BUY	$18.46 - $36.37 $6,184 - $12,183	335 Added 0.08%	426,426 $12.7 Million
Q3 2022 Nov 14, 2022	SELL	$13.55 - $19.92 $194,591 - $286,071	-14,361 Reduced 3.26%	426,091 $8.28 Million
Q2 2022 Aug 11, 2022	SELL	$7.4 - $15.07 $15,710 - $31,993	-2,123 Reduced 0.48%	440,452 $5.97 Million
Q1 2022 May 11, 2022	BUY	$11.65 - $19.57 $593,334 - $996,700	50,930 Added 13.0%	442,575 $6.15 Million
Q4 2021 Feb 10, 2022	BUY	$18.01 - $30.1 $6.98 Million - $11.7 Million	387,542 Added 9445.33%	391,645 $7.46 Million
Q3 2021 Nov 12, 2021	BUY	$18.25 - $38.35 $74,879 - $157,350	4,103 New	4,103 $93,000

Others Institutions Holding NUVL

# of Institutions

209

Shares Held

59.5M

Call Options Held

450K

Put Options Held

619K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.35B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Nuvalent, Inc. Transaction History